AR-V7 – a novel predictive and prognostic biomarker: Individualized therapy for castration-resistant prostate cancer [AR-V7 – ein neuer prädiktiver und prognostischer Biomarker: Therapieindividualisierung beim kastrationsresistenten Prostatakarzinom]

被引：0
|
作者：
Oing C. [1 ]
von Amsberg G. [1 ]
Bokemeyer C. [1 ]
机构：
[1] II. Medizinische Klinik – Onkologie, Hämatologie und Stammzelltransplantation mit Sektion Pneumologie, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, Hamburg
来源：
Der Onkologe | 2015年 / 21卷 / 9期
关键词：
D O I：
10.1007/s00761-015-3019-9
中图分类号：
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：846 / 847
页数：1
相关论文
共 50 条
  • [1] Identification of AR-V7 downstream genes commonly targeted by AR/AR-V7 and specifically targeted by AR-V7 in castration resistant prostate cancer
    Sugiura, Masahiro
    Sato, Hiroaki
    Okabe, Atsushi
    Fukuyo, Masaki
    Mano, Yasunobu
    Shinohara, Ken-ichi
    Rahmutulla, Bahityar
    Higuchi, Kosuke
    Maimaiti, Maihulan
    Kanesaka, Manato
    Imamura, Yusuke
    Furihata, Tomomi
    Sakamoto, Shinichi
    Komiya, Akira
    Anzai, Naohiko
    Kanai, Yoshikatsu
    Luo, Jun
    Ichikawa, Tomohiko
    Kaneda, Atsushi
    TRANSLATIONAL ONCOLOGY, 2021, 14 (01):
  • [2] AR-V7 splice variant detection and its value as prognostic biomarker in metastatic castration-resistant prostate cancer
    Guerra, A. J.
    Silva, E. Tavares
    Eliseu, M.
    Coucelo, M.
    Ferreira, A. M.
    Simoes, A. T.
    Parada, B.
    do Figueiredo, A.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2023, 53
  • [3] AR-V7-a novel predictive and prognostic Biomarker Therapy Individualization in castration-resistant Prostate Cancer
    Oing, C.
    von Amsberg, G.
    Bokemeyer, C.
    ONKOLOGE, 2015, 21 (09): : 846 - 847
  • [4] Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
    Schlack, Katrin
    Seitzer, Konstantin
    Wuestmann, Neele
    Humberg, Verena
    Grundmann, Norbert
    Steinestel, Julie
    Tiedje, Dorothee
    Rahbar, Kambiz
    Krabbe, Laura-Maria
    Boegemann, Martin
    Schrader, Andres J.
    Bernemann, Christof
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [5] Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
    Katrin Schlack
    Konstantin Seitzer
    Neele Wüstmann
    Verena Humberg
    Norbert Grundmann
    Julie Steinestel
    Dorothee Tiedje
    Kambiz Rahbar
    Laura-Maria Krabbe
    Martin Bögemann
    Andres J. Schrader
    Christof Bernemann
    Scientific Reports, 12
  • [6] AR-V7 as a predictive Biomarker for Prostate Cancer - "more than just prophecy?"
    Bernemann, C.
    Krabbe, L. -M.
    UROLOGE, 2020, 59 (01): : 80 - 83
  • [7] The association of AR-V7 with resistance to Abiraterone in metastatic castration-resistant prostate cancer
    Wang, Shuo
    Cao, Yudong
    Tang, Xingxing
    Yang, Xiao
    Ma, Jinchao
    Yu, Ziyi
    Yang, Yong
    Du, Peng
    JOURNAL OF MENS HEALTH, 2022, 18 (03)
  • [8] CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer
    Bastos, Diogo A.
    Antonarakis, Emmanuel S.
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2018, 18 (02) : 155 - 163
  • [9] Nuclear localized AR-V7 protein as a predictive biomarker for treatment selection in metastatic castration resistant prostate cancer (mCRPC)
    Scher, Howard I.
    Lu, David
    Schreiber, Nicole A.
    Louw, Jessica
    Graf, Ryon P.
    Johnson, Ann
    Jendrisak, Adam
    Heller, Glenn
    Bambury, Richard
    Alverez, Herbert A. Vargas
    McLaughlin, Brigit
    Wahl, Justin
    Greene, Stephanie
    Fleisher, Martin
    Dittamore, Ryan
    CANCER RESEARCH, 2016, 76
  • [10] AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients
    Okegawa, Takatsugu
    Ninomiya, Naoki
    Masuda, Kazuki
    Nakamura, Yu
    Tambo, Mitsuhiro
    Nutahara, Kikuo
    PROSTATE, 2018, 78 (08): : 576 - 582
12345